A prospective randomized study comparing tacrolimus and sirolimus versus cyclosporine and methotrexate as gvhd prophylaxis in allogeneic hematopoietic stem cell transplantation

被引：0
|
作者：
Torlen, J. [1 ,2 ]
Ringden, O. [1 ]
Garming-Legert, K. [3 ]
Ljungman, P. [1 ,4 ,5 ]
Winiarski, J. [6 ]
Remes, K. [7 ,8 ]
Itala-Remes, M. [7 ]
Remberger, M. [1 ,2 ]
Mattsson, J. [1 ,2 ]
机构：
[1] Karolinska Inst, Karolinska Univ Hosp, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden
[2] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[3] Karolinska Inst, Karolinska Univ Hosp, Dept Dent Med, Div Oral & Maxillofacial Surg, Stockholm, Sweden
[4] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[5] Karolinska Inst, Karolinska Univ Hosp, Div Hematol, Dept Med, Stockholm, Sweden
[6] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden
[7] Turku Univ Hosp, Dept Internal Med, FIN-20520 Turku, Finland
[8] Turku Univ, Turku, Finland
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O032
引用
下载
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [41] GvHD prophylaxis with everolimus and mycophenolate in allogeneic hematopoietic cell transplantation
    Marks, R.
    Bertz, H.
    Waesch, R.
    Blueme, J.
    Melchinger, W.
    Finke, J.
    ONKOLOGIE, 2012, 35 : 209 - 209
  • [42] Pharmacokinetics of different tacrolimus formulations for GVHD prevention after allogeneic hematopoietic stem cell transplantation
    Marco, D. N.
    Gutierrez-Garcia, G.
    Monge, I.
    Riu, G.
    Carcelero, E.
    Roma, J. R.
    Suarez-Lledo, M.
    Salas, M. Q.
    Martinez-Cibrian, N.
    Pedraza, A.
    Domenech, A.
    Rosinol, L.
    Fernandez-Aviles, F.
    Rovira, M.
    Martinez, C.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 206 - 206
  • [43] Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant
    Mirza, Sayeef
    Tandon, Ankita
    Jenneman, Dakota
    Cao, Shu
    Kumar, Ambuj
    Kidd, Michelle R.
    Khimani, Farhad
    Mishra, Asmita
    Liu, Hien D.
    Nishihori, Taiga
    Perez, Lia
    Bejanyan, Nelli
    Pidala, Joseph
    Nieder, Michael
    Elmariah, Hany
    BLOOD, 2019, 134
  • [44] Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis
    Inamoto, Yoshihiro
    Martin, Paul J.
    Flowers, Mary E.
    Urbano-Ispizua, Alvaro
    Wang, Tao
    Hemmer, Michael T.
    Cutler, Corey S.
    Couriel, Daniel R.
    Alousi, Amin M.
    Arora, Mukta
    Spellman, Stephen R.
    BLOOD, 2014, 124 (21)
  • [45] Comparison of Cyclosporine and Methotrexate with Cyclosporine and Mycophenolate Mofetil for Gvhd Prophylaxis in Myeloablative Allogeneic Bone Marrow Transplantation
    Dean, Robert
    Rybicki, Lisa
    Sobecks, Ronald
    Copelan, Edward
    Kalaycio, Matt
    Andresen, Steven
    Sungren, Shawnda
    Serafin, Mary
    Bolwell, Brian J.
    BLOOD, 2008, 112 (11) : 781 - 781
  • [46] GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study
    R Parody
    L López-Corral
    O Lopez-Godino
    C Martinez
    R Martino
    C Solano
    P Barba
    D Caballero
    I García-Cadenas
    J L Piñana
    F J Marquez-Malaver
    L Vazquez
    A Esquirol
    J C H Boluda
    F Sanchez-Guijo
    J A Pérez-Simon
    Bone Marrow Transplantation, 2016, 51 : 1524 - 1526
  • [47] GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study
    Parody, R.
    Lopez-Corral, L.
    Lopez-Godino, O.
    Martinez, C.
    Martino, R.
    Solano, C.
    Barba, P.
    Caballero, D.
    Garcia-Cadenas, I.
    Pinana, J. L.
    Marquez-Malaver, F. J.
    Vazquez, L.
    Esquirol, A.
    Boluda, J. C. H.
    Sanchez-Guijo, F.
    Perez-Simon, J. A.
    BONE MARROW TRANSPLANTATION, 2016, 51 (11) : 1524 - 1526
  • [48] Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch
    Al Malki, Monzr M.
    Gendzekhadze, Ketevan
    Yang Dongyun
    Mokhtari, Sally
    Parker, Pablo
    Karanes, Chatchada
    Palmer, Joycelynne
    Snyder, David
    Forman, Stephen J.
    Nademanee, Auayporn
    Nakamura, Ryotaro
    TRANSPLANTATION, 2020, 104 (05) : 1070 - 1080
  • [49] Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402)
    Gooptu, Mahasweta
    Kim, Haesook T.
    Howard, Alan
    Choi, Sung W.
    Soiffer, Robert J.
    Antin, Joseph H.
    Ritz, Jerome
    Cutler, Corey S.
    BLOOD, 2018, 132
  • [50] Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors
    L E Perez
    H Fernandez
    E Ayala
    F Beato
    A Neuger
    J Pidala
    M J Schell
    C Anasetti
    Bone Marrow Transplantation, 2017, 52 : 627 - 629
12345